BRM Targeting Compounds and Associated Methods of Use
US-2024190886-A1 · Jun 13, 2024 · US
CDK inhibitors
US9102682B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9102682-B2 |
| Application number | US-201414452296-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 5, 2014 |
| Priority date | Oct 25, 2010 |
| Publication date | Aug 11, 2015 |
| Grant date | Aug 11, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound of formula: or a pharmaceutically acceptable salt thereof, wherein: each R 1 is independently hydrogen, aryl, alkyl, or haloalkyl, wherein each of said alkyl and haloalkyl groups optionally includes O or N heteroatoms in place of a carbon in the chain and two R 1 's on adjacent ring atoms can optionally form a 3-8-membered cycle; and R x is halo, cyano, nitro, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkyl. 2. The compound of claim 1 having formula: 3. The compound of claim 1 having formula: 4. The compound of claim 1 having formula: 5. The compound of claim 1 , wherein R x is C 1 -C 4 alkyl. 6. The compound of claim 2 , wherein R x is C 1 -C 4 alkyl. 7. The compound of claim 3 , wherein R x is C 1 -C 4 alkyl. 8. The compound of claim 4 , wherein R x is C 1 -C 4 alkyl. 9. The compound of claim 1 , wherein R x is halogen. 10. The compound of claim 2 , wherein R x is halogen. 11. The compound of claim 3 , wherein R x is halogen. 12. The compound of claim 4 , wherein R x is halogen. 13. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof. 14. A pharmaceutical composition comprising the compound of claim 2 , or a pharmaceutically acceptable salt thereof. 15. A pharmaceutical composition comprising the compound of claim 3 , or a pharmaceutically acceptable salt thereof. 16. A pharmaceutical composition comprising the compound of claim 4 , or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
- C07D487/14Primary
Ortho-condensed systems · CPC title
spiro-condensed · CPC title
Ortho-condensed systems · CPC title
Spiro-condensed systems · CPC title
Spiro-condensed pyrazines or piperazines · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9102682B2 cover?
- Compounds of formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
- Who is the assignee on this patent?
- G1 Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D487/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).